bmiMD vs NP2GO
An in-depth comparison of two leading GLP-1 Providers
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Two GLP-1 Providers chasing the same patients, trading off price, geography and what lands in the box differently. On our scoring, bmiMD opens cheaper — $99/mo against $150, and bmiMD finishes ahead, 9.1 to 6.8. What follows: the prices, what each plan actually covers, the six-dimension score, where each one is weak, and who should pick which.
Pricing
bmiMD
Ladder by plan length: 12 mo $99/mo (Total $1,188.00), 6 mo $109/mo, 3 mo $119/mo, 1 mo $129/mo. 'Same price at every dose'; provider visit + free shipping included. Verified 2026-07-14 at bmimd.com/personalized-glp-1/ and /semaglutide-injection/.
Ladder by plan length: 12 mo $139/mo (Total $1,668.00), 6 mo $149/mo, 3 mo $159/mo, 1 mo $179/mo. Same flat-dose model. Verified 2026-07-14 at bmimd.com/tirzepatide-injection/.
Strike-through pricing shown: $151.20 -> $99/mo (12-mo) up to $199.80 -> $129/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-microdose/.
Strike-through pricing shown: $250.20 -> $139/mo (12-mo) up to $299.70 -> $179/mo (monthly), labeled 'Limited time offer'. bmimd.com/glp-1-gip-microdose/.
NP2GO
What’s included
bmiMD
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
NP2GO
Inclusions not disclosed.
Score breakdown
Both providers are scored on the same six-dimension framework. The gradient bar marks the stronger side on each dimension.
bmiMD
9.1/10
NP2GO
6.8/10
Value25%
Effectiveness25%
User Experience15%
Trust & Safety15%
Accessibility10%
Support10%
Features & Coverage
| Feature | bmiMD | NP2GO |
|---|---|---|
| Starting Price | ✓$99/mo | $150/mo |
| Features | 2 features | ✓8 features |
| States Available | ✓50 | 40 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
About bmiMD
bmiMD is a medical weight loss clinic that prescribes GLP-1 medications through telehealth.
Read our full bmiMD review →About NP2GO
The full pricing matrix for compounded semaglutide and compounded tirzepatide is published openly, split two ways: Pay As You Go, billed per dose, where a visit fee of $99 falls every 3 months; or a flat membership month to month. Semaglutide enters at $150/mo. Nurse practitioners lead the operation, which runs a clinic in Edmond, Oklahoma alongside telehealth, dates to 2019, and belongs to the Obesity Medicine Association. Weight-loss visits by video cover 39 states and DC.
Read our full NP2GO review →Pros & Cons
bmiMD
What we like
- Semaglutide at $99 a month, 48% below the $189 median for the same drug and form across this register
- Tirzepatide at $139 a month, 48% below the $267 median for the same drug and form across this register
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- Coverage is published for all 50 states
- No FDA warning letter matched this operator when we searched our enforcement register
Watch-outs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
NP2GO
What we like
- Semaglutide at $150 a month, within the normal band around this register's $189 median for the same drug and form
- Coverage is published for 40 states
- No FDA warning letter matched this operator when we searched our enforcement register
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Watch-outs
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
Our Verdict
bmiMD takes it, 9.1 against 6.8, and it is especially strong on starting below a standard dose, with microdose tiers. NP2GO is no weak second and may fit you better on compounded semaglutide at $150/month.
Choose bmiMD if…
You want starting below a standard dose, with microdose tiers and an opening price near $99 a month.
Choose NP2GO if…
You want compounded semaglutide at $150/month and an opening price near $150 a month.
Ready to start? Vetted GLP-1 providers
Vetted telehealth providers that prescribe GLP-1 online.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Telos Rx
Starting below a standard dose, with microdose tiers
From $49/mo
Get started →MyDrHank
An oral route if you will not self-inject
From $25/mo
Get started →SkinnyRx
Starting below a standard dose, with microdose tiers
From $149.25/mo
Get started →bmiMD vs NP2GO: FAQ
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Related comparisons
Continue exploring bmiMD and NP2GO head-to-heads in the same category.
- bmiMD vs Trimi Health
- bmiMD vs Embody
- bmiMD vs He & She MD
- NP2GO vs Lean Meds
- NP2GO vs NextMeds
- NP2GO vs CoreAge Rx
Or see the full category ranking.
Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.